Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment approaches.
Modern imaging studies in CRPCA have become more and more complex and selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Editor's comments This article gives some experimental backround to the clinical observation (albeit in only small series so far) of cross resistance between docetaxel, abiraterone and enzalutamide. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer European Journal of Cancer, Volume 49, Issue 18, December 2013, Pages 3821-3830
Editor's comments: This, to the best of my knowledge , is the first report demonstrating an abiraterone withdrawal effect (similar to anti-androgen withdrawal). More data is required to better assess the potential of ... Biochemical and objective response to abiraterone acetate withdrawal: Incidence and clinical relevance of a new scenario for castration-resistant prostate cancer Urology, Volume 82, Issue 5, November 2013, Pages 1090-1093.
Editor's comments: This study adds to the long list of failures when compounds were combined with Docetaxel in mCRPC patients. Although effects of Dasatinib particularly in the bone environment were encouraging in ... Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial The Lancet Oncology, Volume 14, Issue 13, December 2013, Pages 1307-1316.
About the Editor
Kurt Miller MD, PhDProfessor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the ... Read more »
16 March - 18 March
67th Annual Scientifi c Meeting of the Urological Society of Australia and New Zealand (USANZ)
Tel.: +61 2 9362 8644
Fax: +61 2 9362 143
25 March - 29 March
XXXVIII International Congress of the Colegio Mexicano de Urología Nacional
San Luis Potosí, Mexico
Tel.: +55 9000 2092
Fax: +55 9000 2092
4 April - 8 April
Contact: ESTRO Head Offi ce
Tel.: +32 2 775 93 40
Fax: +32 2 779 54 94